KH906, a recombinant human VEGF receptor fusion protein, is a new effective topical treatment for corneal neovascularization

Molecular Vision

Volumn 17, Issue , 2011, Pages 797-803

  Li, Tao ^a   Hu, Andina ^a   Li, Shiqing ^a   Luo, Yan ^a   Huang, Juan ^a   Yu, Honghua ^a   Ma, Wei ^a   Pan, Jianying ^a   Zhong, Qi ^b   Yang, Jin ^b   Wu, Jianming ^b   Tang, Shibo ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b Chengdu Kanghong Biotechnology Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE EYE; BEVACIZUMAB; DEXAMETHASONE; KH 906; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ANALYSIS; NONHUMAN; PRIORITY JOURNAL; SLIT LAMP;

ADMINISTRATION, TOPICAL; ANGIOGENESIS INHIBITORS; ANIMALS; BURNS, CHEMICAL; CORNEA; CORNEAL NEOVASCULARIZATION; FLUORESCEIN; HUMANS; OPHTHALMIC SOLUTIONS; RABBITS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; SODIUM HYDROXIDE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 79955578424     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Chang JH, Gabison EE, Kato T, Azar DT. The Azar DT. Corneal neovascularization. Curr Opin Ophthalmol 2001; 12:242-249. [PMID: 11507336]
2. Dana MR, Schaumberg DA, Kowal VO, Goren MB, Rapuano CJ, Laibson PR, Cohen EJ. Corneal neovascularization after penetrating keratoplasty. Cornea 1995; 14:604-609. [PMID: 8575183]
3. Lee P, Wang CC, Adamis AP. Ocular neovascularization: epidemiologic review. Surv Ophthalmol 1998; 43:245-269. [PMID: 9862312]
4. Azar DT. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2006; 104:264-302. [PMID: 17471348]
5. Hosseini H, Nejabat M. A potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents. Med Hypotheses 2007; 68:799-801. [PMID:17107753]
6. Gan L, Fagerholm P, Palmblad J. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand 2004; 82:557-563. [PMID: 15453853]
7. Phillips GD, Stone AM, Jones BD, Schultz JC, Whitehead RA, Knighton DR. Vascular endothelial growth factor (rhVEGF165) stimulates direct angiogenesis in the rabbit cornea. In Vivo 1994; 8:961-965. [PMID: 7539637]
8. Gan L, Fagerholm P, Palmblad J. Vascular endothelium growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand 2004; 82:557-563. [PMID: 15453853]
9. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 2000; 41:2514-2522. [PMID: 10937562]
10. Cursiefen C, Cao J, Chen L, Liu Y, Maruyama K, Jackson D, Kruse FE, Wiegand SJ, Dana MR, Streilein JW. Inhibition of lymphagiogenesis and hemangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 2004; 45:2666-2673. [PMID: 15277490]
11. Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 2008; 115:e33-38. [PMID: 18439681]
12. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113:363-372. [PMID: 16458968]
13. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, Michels S, MarcusEN, Lenchus JD, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open label clinical study. Ophthalmology 2006; 113:2002.e1-e12. [PMID: 17027972]
14. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006; 142:1-9. [PMID: 16815245]
15. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006; 26:352-354. [PMID: 16508438]
16. Papathanassiou M, Theodossiadis PG, Liarakos VS, Rouvas A, Giamarellos-Bourboulis EJ, Vergados IA. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol 2008; 145:424-431. [PMID: 18207123]
17. Hosseini H, Nejabat M, Mehryar M, Yazdchi T, Sedaghat A, Noori F. Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. Clin Experiment Ophthalmol 2007; 35:745-748. [PMID: 17997779]
18. Dratviman-Storobinsky O, Lubin BC, Hasanreisoglu M, Goldenberg-Cohen N. Effect of subconjuctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization. Mol Vis 2009; 5:2326-2338. [PMID:19936307]
19. Zhang M, Zhang J, Yan M, Li H, Yang C, Yu D. Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choroidal neovascularization in monkeys. Mol Vis 2008; 14:37-49. [PMID: 18246030]
20. Murata M, Shinji S, Saburo H, Masayuki T. Inhibitory effect of triamcinolone acetonide on corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2006; 244:205-209. [PMID: 16044325]
21. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91:4082-4085. [PMID: 7513432]
22. Bhattacharjee PS, Huq TS, Mandal TK, Graves RA, Muniruzzaman S, Clement C, McFerrin HE, Hill JM. A novel peptide derived from human apolipoprotein E is an inhibitor of tumor growth and ocular angiogenesis. PLoS ONE 2011; 6:e15905. [PMID: 21253017]
23. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmacother 2007; 41:614-625. [PMID:17355998]
24. Chung JH, Kang YG, Kim HJ. Effect of 0.1% dexamethasone on epithelial healing in experimental corneal alkali wounds: morphological changes during the repair process. Graefes Arch Clin Exp Ophthalmol 1998; 236:537-545. [PMID:9672801]
25. Sarchahi AA, Maimandi A, Tafti AK, Amani M. Effects of acetylcysteine and dexamethasone on experimental corneal wounds in rabbits. Ophthalmic Res 2008; 40:41-48. [PMID:18025839]
26. Dan L, Shi-long Y, Miao-li L, Yong-ping L, Hong-jie M, Ying Z, Xiang-gui W. Inhibitory effect of oral doxycycline on neovascularization in a rat corneal alkali burn model ofangiogenesis. Curr Eye Res 2008; 33:653-660. [PMID:18696340]
27. Nirankari VS, Baer JC. Corneal argon laser photocoagulation for neovascularization in penetrating keratoplasty. Ophthalmology 1986; 93:1304-1309. [PMID: 2431371]
28. Pillai CT, Dua HS, Hossain P. Fine needle diathermy occlusion of corneal vessels. Invest Ophthalmol Vis Sci 2000; 41:2148-153. [PMID: 10892856]
29. Gohto Y, Obana A, Kaneda K, Miki T. Photodynamic effect of a new photosensitizer ATX-S10 on corneal neovascularization. Exp Eye Res 1998; 67:313-322. [PMID:9778412]
30. Fossarello M, Peiretti E, Zucca I, Serra A. Photodynamic therapy of corneal neovascularization with verteporfin. Cornea 2003; 22:485-488. [PMID: 12827058]
31. Hurmeric V, Mumcuoglu T, Erdurman C, Kurt B, Dagli O, Durukan AH. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs. Cornea 2008; 27:357-362. [PMID: 18362668]
32. DeStafeno JJ, Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol 2007; 125:834-836. [PMID: 17562998]
33. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002; 2:795-803. [PMID: 12360282]